Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

The Zacks Analyst Blog Highlights: Alibaba, General Electric, Anthem, Progressive And Pharmaceuticals

Published 11/07/2019, 09:49 PM
Updated 07/09/2023, 06:31 AM

For Immediate Release

Chicago, IL – November 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alibaba Group (NYSE:BABA) , General Electric (NYSE:GE) , Anthem (NYSE:ANTM) , Progressive (NYSE:PGR) and Regeneron Pharmaceuticals (NASDAQ:REGN) .

Here are highlights from Thursday’s Analyst Blog:

Top Stock Reports for Alibaba, GE and Anthem

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group, General Electric and Anthem. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Alibaba’s shares have underperformed the Zacks Internet Commerce industry year to date (34.4% vs. 27.6%). The Zacks analyst believes that Alibaba’s strengthening cloud business with its expanding customer base drove its performance.

Alibaba reported strong fiscal second-quarter earnings driven by steady improvement in core commerce and solid growth in metrics. Notably, the New Retail strategy has gained momentum in the markets served by the company. This aided growth in Tmall Import and Hema fresh food grocery businesses.

However, revenues missed the Zacks Consensus estimate due to higher expenses. The company’s increasing investments, uncertain economy and macro headwinds in China are major concerns. Also, rising competition poses a risk.

Shares of General Electric have gained 8.5% in the past six months against S&P 500’s rise of 6.7%. The Zacks analyst believes that in the quarters ahead, the company is poised to gain from its portfolio restructuring program, digital business, efforts to reduce leverage, international commercial presence and improvement in segmental businesses.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

It expects adjusted earnings per share of 55-65 cents for 2019. Healthy business in Aviation, Healthcare and Renewable Energy segments as well as steps to improve the Power segment and asset dispositions in GE Capital will be boons. In third-quarter 2019, the company’s earnings surpassed estimates by 25%, while revenues lagged the same by 19.8%.

The presence of internal and external challenges remains a drag for the Power business. Also, weak margin in Renewable Energy, forex woes and tariffs might adversely impact performance.

Anthem’s shares have declined 3.9% over the past three months against the Zacks Medical Insurance industry’s rise of 0.3%. The Zacks analyst believes that the company’s prudent acquisitions and collaborations complement its organic growth and helps it boost Medicare Advantage growth.

It has launched successful partnerships with various companies and it expects its partnership model to accelerate growth. Its growing top line paves the way for long-term growth. A diverse product portfolio also helped it enhance its revenues. Its strong capital position and solid guidance also impress.

Its third-quarter 2019 earnings of $4.87 per share surpassed the Zacks Consensus Estimate by 0.6% and grew 27.8% year over year on higher revenues. However, it has been suffering from high benefit costs and selling, general and administrative expense, which continues to weigh on its bottom line. Rising level of debt is another concern.

Other noteworthy reports we are featuring today include Progressive and Regeneron Pharmaceuticals.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Click for details >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



Alibaba Group Holding Limited (BABA): Free Stock Analysis Report

General Electric Company (GE): Free Stock Analysis Report

The Progressive Corporation (PGR): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.